MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- Conceptus, Inc. (Nasdaq: CPTS) developer of the Essure(R) procedure, the first and only non-incisional permanent birth control method available, today reported that Medi-Cal, California's state fee-for-service Medicaid program, is now covering the Essure procedure. Low-income or disabled women in California now have a safe and effective permanent female birth control option that does not require the general anesthesia, incisions or long recovery period of traditional tubal ligation.
"We are very happy that Medi-Cal has completed its review of the safety and efficacy of the Essure device and has established coverage for this procedure," said California Assembly Speaker pro Tem Sally Lieber. "This is a great day for the women of California covered by Medicaid, who will now be able to avoid the risks and long recovery times associated with traditional tubal ligation surgery."
The Essure procedure is now a covered procedure for Medi-Cal beneficiaries that are 21 years of age or older. Physicians may perform the Essure procedure in the physician's office, the ambulatory surgery center or the hospital outpatient department. Medi-Cal is expected to pay $2,282 as a global fee for an in-office procedure. This coverage decision impacts approximately 3.8 million Californians.
Coverage of the Essure procedure enables state Medicaid programs to provide a safe, convenient and economical choice for preventing pregnancies. In addition, the shorter recovery time-typically one day as compared with four to six days for the traditional laparoscopic procedure-means a faster return to work or home responsibilities. California joins 45 other states now covering the Essure procedure for women enrolled in Medicaid. Conceptus has yet to receive Medicaid decisions for the Essure procedure in Arizona, Nebraska, North Dakota, Utah and Washington.
"We continue to provide compelling information on the costs and benefits of the Essure procedure to those few remaining state Medicaid programs that have not given a coverage decision, and to lobby for improved payment in those states with poor reimbursement," commented Mark Sieczkarek, president and chief executive officer of Conceptus. "This positive coverage decision from Medi-Cal is an important step in our efforts to make Essure available to women from all socioeconomic backgrounds."
About the Essure Procedure
The Essure procedure, approved by the FDA in 2002, is a permanent birth control procedure that replaces tubal ligation for women. In the comfort of a physician's office and in about 10 minutes, the soft micro-inserts are placed into the Fallopian tubes through the cervix eliminating the need for incisions. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the Fallopian tubes.
The Essure confirmation test is performed three months after the procedure to confirm that the micro-inserts are in the correct location, the tubes are blocked and that the woman can discontinue temporary birth control. The Essure procedure is 99.80% effective and is the first and only FDA approved female sterilization procedure to have zero pregnancies in clinical trials.
Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.
Additional information about the Essure procedure is available at http://www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at http://www.conceptus.com or by calling 1-877-ESSURE2.
Except for the historical information contained herein, the matters
discussed in this press release are forward-looking statements, the
accuracy of which is necessarily subject to risks and uncertainties.
Discussions regarding the continued availability of Medicaid coverage, and
the Company's ability to obtain Medicaid coverage from additional states,
among other matters discussed in this release, may differ significantly
from the discussion of such matters in the forward-looking statements. Such
differences may be based upon factors such as strategic planning decisions
by management, re-allocation of internal resources, decisions by insurance
companies, scientific advances by third parties, and introduction of
competitive products, as well as those factors set forth in the Company's
most recent Annual Report on Form 10-K and most recent Quarterly Report on
Form 10-Q, and other filings with the Securities and Exchange Commission.
310-577-7870 x 111
|SOURCE Conceptus, Inc.|
Copyright©2008 PR Newswire.
All rights reserved